Skip to content
Agentic OS
Menu

Intelligence / Healthtech / FDA 510(k) Clearances / Neuroxt, Inc.

Approvalsdevice cleared8 Oct 2026

Neuroxt, Inc.

8 Oct 2026: Device cleared · NEXT-Cue. Recorded in the openFDA device 510(k) data.

View the source record

Decided
8 Oct 2026
Device
NEXT-Cue
Specialty
Neurology
Country
South Korea
Location
Seoul
Clearance type
Traditional
510(k) number
K261805
Submitted
2026-06-01
What this signal means

A clearance starts commercialisation: distribution, reimbursement, software and sales hires.

  1. 268 added in the 30 days to 9 Nov 2026.
  2. Cardiovascular leads with 122 clearances, then Radiology (107).
Reach them with AOS

Find the decision makers at Neuroxt, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

More in Neurology

FDA 510(k) Clearances

See all

Source: openFDA device 510(k) data, data to 9 Nov 2026. Devices FDA found substantially equivalent and cleared for the US market. Decision dates as published by FDA. AOS shows what the public record says; it does not verify or endorse the company.